If you look at the previous conference poster presentation on interim herVaxx results, they had figures for both OS (0.416 i think) and PFS (0.53 I think).
So this updated result is a step backwards.
BUT, still possible to completely disrupt the Her2 mAb market due to the other benefits of herVaxx.
Add to My Watchlist
What is My Watchlist?